Abstracts tagged "polymorphism and rheumatoid arthritis (RA)"

Abstract Number: 2483 • 2012 ACR/ARHP Annual Meeting
Folic Acid Pathway Single Neucelotide Polymorphisms Associated with Methotrexate-Related Significant Adverse Events
Lisa A. Davis¹, Brooke Ivan Polk², Alyse D. Mann³, Roger K. Wolff⁴, Gail S. Kerr⁵, Andreas M. Reimold⁶, Grant W. Cannon⁷, Ted R. Mikuls⁸ and Liron Caplan⁹, ¹Div of Rheumatology, Univ of Colorado School of Med, Aurora, CO, ²University of Colorado Medical School, Aurora, CO, ³Research, Denver VA Medical Center, Denver, CO, ⁴University of Utah, Salt Lake City, UT, ⁵Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁶Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁷Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁸Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁹Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Methotrexate (MTX) is the cornerstone medication in the treatment of rheumatoid arthritis (RA). While MTX has been associated with a number of adverse…
Abstract Number: 1179 • 2012 ACR/ARHP Annual Meeting
Vitamin D Receptor Polymorphisms Are Associated with Clinical Outcomes and IgM Responses to Common Pathogens but Not Baseline Disease Activity in Early Inflammatory Arthritis
Carol A. Hitchon¹, Linda Larcombe¹, Neeloffer Mookherjee², Christine A. Peschken³, Marianna M. Newkirk⁴ and Hani S. El-Gabalawy⁵, ¹University of Manitoba, Winnipeg, MB, Canada, ²Centre for Proteomics, University of Manitoba, Winnipeg, MB, Canada, ³RR 149G, University of Manitoba, Winnipeg, MB, Canada, ⁴Medicine, McGill University Health Centre, Montreal, QC, Canada, ⁵Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Vitamin D (VitD) exerts immunoregulatory activities of potential importance to rheumatoid arthritis and acts by binding to nuclear vitamin D receptors (VDRs) and regulating…
Abstract Number: 1186 • 2012 ACR/ARHP Annual Meeting
A Single Nucleotide Polymorphism of Tumor Necrosis Factor Receptor-Associated Factor 1 Predicts Clinical Response to Anti-Tumor Necrosis Factor Treatments in Japanese Patients with Rheumatoid Arthritis
Tetsuya Nishimoto¹, Noriyuki Seta², Ryusuke Anan², Tatsuya Yamamoto², Yuko Kaneko³, Masataka Kuwana⁴ and Tsutomu Takeuchi⁵, ¹Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Department of Internal Medicine, Keio university, Tokyo, Japan, ³Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Recent genome-wide association studies have disclosed several single nucleotide polymorphisms (SNPs) associated with rheumatoid arthritis (RA) susceptibility. Among them, it is reported that the…
Abstract Number: 407 • 2012 ACR/ARHP Annual Meeting
The I50V IL4R SNP Is Associated with Increased Th17 Cell Frequency and Poor Clinical Outcome in Rheumatoid Arthritis
Jan Leipe¹, Iryna Prots², Markus A. Schramm¹, Matthias Witt¹, Axel P. Nigg¹, Christiane S. Reindl¹, Claudia Dechant¹, Mathias Grunke¹, Hendrik Schulze-Koops¹ and Alla Skapenko³, ¹Division of Rheumatology and Clinical Immunology, Med. Klinik und Poliklinik IV, University of Munich, Munich, Germany, ²Friedrich-Alexander-University Erlangen-Nürnberg, Junior Research Group III, Interdisciplinary Center for Clinical Research Nikolaus-Fiebiger Center for Molecular Medicine, Erlangen, ³Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany
Background/Purpose: A single nucleotide polymorphism (SNP) in the IL4R gene (I50V, rs 1805010) has previously been associated with an aggressive destructive course of rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].